Novo Nordisk and Viatris have agreed to resolve a patent dispute related to Novo's blockbuster weight-loss drugs Ozempic and ...

We recently made a list of 10 Best NASDAQ Stocks Under $20 to Buy. In this piece, we will look at where Viatris Inc.

NORTHAMPTON, MA / ACCESSWIRE / October 7, 2024 / Viatris Across all Viatris locations, we are committed to protecting ...

Novo Nordisk (NVO) and Viatris (VTRS) have reportedly reached an agreement in their dispute over U.S. patents protecting Novo ...

Viatris (VTRS) reported positive top-line results of Phase 3 study in Japan evaluating the safety and efficacy of EFFEXOR in adults ...

On Tuesday, Viatris Inc (VTRS) stock saw a decline, ending the day at $11.32 which represents a decrease of $-0.01 or -0.09% from the prior close of $11.33. The stock opened at $11.33 and touched a ...

Alongside the settlement, Novo and Viatris have asked the U.S. Patent and Trademark Office to terminate its review of the ...

Novo Nordisk ($NVO) and Viatris ($VTRS) have agreed to settle a dispute over patents for Novo’s weight-loss drugs, Ozempic ...

With a new patent settlement, generic partners Mylan and Natco have cleared one hurdle to a potential U.S. launch of their ...

Novo Nordisk (NOV: N) has reached a settlement with Mylan Pharmaceuticals, part of Viatris (Nasdaq: VTRS), concluding a US ...

Viatris, Inc. is a global healthcare company, which engages in the provision of access to medicines and sustainable operations. It also offers support services such as diagnostic clinics ...

In the phase 3b BATURA trial, Airsupra—a pressurized metered-dose inhaler containing albuterol and budesonide—significantly ...